Navigation Links
Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
Date:2/20/2008

RESEARCH TRIANGLE PARK, N.C., Feb. 20 /PRNewswire/ -- Addrenex Pharmaceuticals has reached its first milestone accomplishment this year with the filing of a new drug application (NDA) for its first drug, CloniBID, to treat hypertension. Upon approval from the Food and Drug Administration, Addrenex and its licensing partner Sciele Pharma, Inc. will launch the drug in the first half of 2009.

Addrenex has moved swiftly to develop and commercialize CloniBID, a sustained-release formulation of clonidine hydrochloride. The company recently entered its second year of operation and already has developed and tested its two lead products, CloniBID for hypertension and Clonicel for the treatment of attention deficit hyperactivity disorder (ADHD). Clonicel is currently undergoing phase 3 clinical trials nationwide and will complete the trials by the end of the year.

Both drugs are designed to circumvent the bothersome side effects of generic clonidine, including a peak of sedation when the drug is absorbed and a subsequent rebound of hypertension once the drug's effects wear off. Such unwanted "peaks and troughs" have limited the drug's use in some patients who otherwise have responded very well to the drug's beneficial effects, said Moise Khayrallah, cofounder and CEO of Addrenex.

Last year, Addrenex quickly acquired the necessary data to attract Sciele's interest in licensing the rights to market both drugs. Sciele purchased a $6 million equity stake in Addrenex, with the potential for an additional $11 million in milestone payments. Sciele also holds the first right of refusal to market Addrenex's future products in the areas of pediatrics, women's health, cardiovascular and metabolic diseases.

The agreement with Sciele in June was followed by a second contract in December, granting Addrenex the rights to a vast library of nearly 400 compounds at the University of Nebraska Medical Center. The library of compounds focuses on adrenergic regulation, the basis of Addrenex's drug development efforts.

"We credit our rapid success in developing viable drugs and building partnerships to our nimble, fast-paced business model and outside-the-box thinking," Khayrallah said. "We stay sharply focused on the major milestones that must be accomplished, and we don't allow perceived impediments to hamper our progress."

Addrenex's goal is to develop a diverse pipeline of products aimed at regulating the adrenergic system, a vast and varied regulator of multiple bodily processes. The alpha-2 adrenergic receptors in particular have been implicated in a wide variety of medical conditions, including hypertension, ADHD, menopausal flushing, migraine, sleep disturbances, aggression, pain and addiction.

Few drugs on the market are known to target the alpha-2 adrenergic receptors; hence, Addrenex is seeking to fill a void in this pharmaceutical niche, Khayrallah said.

About Addrenex Pharmaceuticals, Inc.

Addrenex Pharmaceuticals is a focused, specialty pharmaceutical company that develops and commercializes drugs to treat adrenergic dysregulation. Addrenex Pharmaceuticals is based in Durham, North Carolina, on the edge of Research Triangle Park. The company was formed in 2006 by a practicing physician and a drug development expert with the mission to explore the impact that neurotransmitter regulation has on a variety of diseases and disorders. Addrenex identified adrenergic regulation as its initial research focus. Adrenergic dysregulation is implicated in medical conditions such as hypertension, ADHD, migraine, and post-menopausal symptoms. Addrenex will use the knowledge and experience gained from developing CloniBID and Clonicel as the foundation for additional discovery and development in the area of adrenergic regulation.


'/>"/>
SOURCE Addrenex Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
4. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... SC (PRWEB) , ... April 26, 2017 , ... ... mind, has teamed up with NASA to showcase the future of deep space ... Launch System (SLS) rocket and Orion spacecraft and includes a guest appearance by ...
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... headlines and drive high-level conversations among healthcare industry stakeholders, the discussion surrounding the ... – taking place May 15-18, 2017 in Los Angeles, Calif. Hosted by the ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
(Date:4/24/2017)... April 24, 2017  Dante Labs announced today the offer ... 850 (ca. $900). While American individuals have been able to ... Europeans can access WGS below EUR 1,000. The ... leveraging genetic information to make informed decisions about disease monitoring, ... ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
Breaking Biology News(10 mins):